Table 1. Details of CML patients used... | American Society of Hematology

Table 1.

Details of CML patients used for the generation of DCs

Patient no.	Age, y	DRB1^**	Prior treatment^†	Antigen capture^‡	Antigen process/present^‡	Migration^‡	FACS^‡	MLR^‡
1	29	0701, 1302	NO	4	12	3	3	—
2	14	7/17	NO	4	10	3	3	—
3	42	0404/9	NO	—	—	2	1	4
4	39	15/17	NO	—	1	1	1	2
5	32	0401/9	NO	—	—	3	1	2
6	55	15	NO	1	1	1	1	1
7	17	4/7	NO	2	5	—	2	1
8	33	0405/0701	HU	1	5	—	2	1
9	31	17/13	HU	—	—	—	1	—
10	14	7/11	NO	1	—	—	—	—
11	37	0701/1104	HU	1	—	—	—	1
12	29	0402/1303	HU	1	—	—	—	1
13	60	Not done	HU	1	—	—	—	—
14	39	Not done	HU	1	—	—	—	—
15	42	15/15	NO	1	2	—	—	—

Patient no.	Age, y	DRB1^**	Prior treatment^†	Antigen capture^‡	Antigen process/present^‡	Migration^‡	FACS^‡	MLR^‡
1	29	0701, 1302	NO	4	12	3	3	—
2	14	7/17	NO	4	10	3	3	—
3	42	0404/9	NO	—	—	2	1	4
4	39	15/17	NO	—	1	1	1	2
5	32	0401/9	NO	—	—	3	1	2
6	55	15	NO	1	1	1	1	1
7	17	4/7	NO	2	5	—	2	1
8	33	0405/0701	HU	1	5	—	2	1
9	31	17/13	HU	—	—	—	1	—
10	14	7/11	NO	1	—	—	—	—
11	37	0701/1104	HU	1	—	—	—	1
12	29	0402/1303	HU	1	—	—	—	1
13	60	Not done	HU	1	—	—	—	—
14	39	Not done	HU	1	—	—	—	—
15	42	15/15	NO	1	2	—	—	—

— indicates not done; NO, nothing; HU, hydroxyurea.

HLA-DR typing.

Treatment prior to taking of the sample was NO or HU.

Number of functional experiments performed with each preparation of DCs.